Literature DB >> 2868495

Buspirone: anxiolytic?

J C Pecknold, P Familamiri, H Chang, R Wilson, J Alarcia, D J McClure.   

Abstract

Sixty (60) out-patients with DSM III generalized anxiety disorder were treated after a 1-week placebo washout in a 4-week double-blind study with buspirone, diazepam and placebo; after which they were withdrawn abruptly from medication or assigned to a 2-week period of placebo. The HAM-A score was significantly lower in the diazepam group at week 2 (p less than .02) and the buspirone group at week 3 (p less than .04) as compared to the placebo group. A similar pattern was evident in the female group, but not in the male group. Dizziness was the most prominent adverse effect in the buspirone group, whereas the diazepam group had more adverse effects including sedation, fatigue, dizziness and impaired concentration. Withdrawal symptoms were more evident in the diazepam group than the buspirone group.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2868495     DOI: 10.1016/0278-5846(85)90032-6

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

1.  Anti-conflict efficacy of buspirone following acute versus chronic treatment.

Authors:  D M Schefke; D J Fontana; R L Commissaris
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 2.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

Review 3.  Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence.

Authors:  N Andrews; S E File
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Conditioned taste aversion and place preference with buspirone and gepirone.

Authors:  J L Neisewander; S A McDougall; S L Bowling; M T Bardo
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 5.  Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.

Authors:  K L Goa; A Ward
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

Review 6.  Azapirones for generalized anxiety disorder.

Authors:  C A Chessick; M H Allen; Me Thase; A B C Batista Miralha da Cunha; F F K Kapczinski; M S M L de Lima; J J S S dos Santos Souza
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

7.  An overview of Indian research in anxiety disorders.

Authors:  J K Trivedi; Pawan Kumar Gupta
Journal:  Indian J Psychiatry       Date:  2010-01       Impact factor: 1.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.